Nevro Corp. (NVRO)
USD 3.74
(-7.65%)
USD 3.74
(-7.65%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -78.31 Million USD | 56.94% |
| 2022 | 21.02 Million USD | -187.36% |
| 2021 | -102.39 Million USD | -12.86% |
| 2020 | -52.2 Million USD | 34.85% |
| 2019 | -83.35 Million USD | -131.13% |
| 2018 | -37.85 Million USD | -41.12% |
| 2017 | -22.84 Million USD | -35.6% |
| 2016 | -22.04 Million USD | 65.02% |
| 2015 | -62.91 Million USD | -120.33% |
| 2014 | -30.09 Million USD | -12.75% |
| 2013 | -25.1 Million USD | -31.5% |
| 2012 | -19.09 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -20.59 Million USD | 38.12% |
| 2024 Q1 | -28.39 Million USD | -55.24% |
| 2023 Q4 | -8.76 Million USD | 53.58% |
| 2023 Q3 | -18.87 Million USD | 4.9% |
| 2023 FY | - USD | 56.94% |
| 2023 Q1 | -36.32 Million USD | -87.64% |
| 2023 Q2 | -19.84 Million USD | 45.36% |
| 2022 Q4 | -19.35 Million USD | -3.24% |
| 2022 Q2 | -20.55 Million USD | 31.57% |
| 2022 Q1 | -30.03 Million USD | -14.58% |
| 2022 FY | - USD | -187.36% |
| 2022 Q3 | -18.75 Million USD | 8.77% |
| 2021 Q2 | -13.58 Million USD | 34.31% |
| 2021 FY | - USD | -12.86% |
| 2021 Q3 | -24.12 Million USD | -77.57% |
| 2021 Q1 | -20.68 Million USD | -2264.0% |
| 2021 Q4 | -26.21 Million USD | -8.65% |
| 2020 Q4 | -875 Thousand USD | 36.82% |
| 2020 Q3 | -1.38 Million USD | 95.79% |
| 2020 Q2 | -32.87 Million USD | -67.43% |
| 2020 FY | - USD | 34.85% |
| 2020 Q1 | -19.63 Million USD | -68.08% |
| 2019 Q3 | -12.75 Million USD | 51.98% |
| 2019 Q2 | -26.56 Million USD | 32.14% |
| 2019 Q1 | -39.14 Million USD | -354.96% |
| 2019 FY | - USD | -131.13% |
| 2019 Q4 | -11.68 Million USD | 8.42% |
| 2018 Q2 | -6.7 Million USD | 52.09% |
| 2018 Q3 | -7.01 Million USD | -4.59% |
| 2018 Q4 | -8.6 Million USD | -22.65% |
| 2018 FY | - USD | -41.12% |
| 2018 Q1 | -13.99 Million USD | -544.43% |
| 2017 Q2 | -8.15 Million USD | 28.02% |
| 2017 FY | - USD | -35.6% |
| 2017 Q4 | -2.17 Million USD | 19.35% |
| 2017 Q3 | -2.69 Million USD | 66.97% |
| 2017 Q1 | -11.32 Million USD | -80.67% |
| 2016 Q1 | -7.93 Million USD | 39.65% |
| 2016 Q2 | -5.89 Million USD | 25.72% |
| 2016 Q3 | -592 Thousand USD | 89.95% |
| 2016 FY | - USD | 65.02% |
| 2016 Q4 | -6.26 Million USD | -958.95% |
| 2015 Q4 | -13.14 Million USD | 25.78% |
| 2015 Q3 | -17.7 Million USD | 5.83% |
| 2015 Q2 | -18.8 Million USD | -52.41% |
| 2015 Q1 | -12.33 Million USD | -73.64% |
| 2015 FY | - USD | -120.33% |
| 2014 Q1 | -6.94 Million USD | -6.61% |
| 2014 FY | - USD | -12.75% |
| 2014 Q4 | -7.1 Million USD | -9.36% |
| 2014 Q3 | -6.49 Million USD | 10.52% |
| 2014 Q2 | -7.26 Million USD | -4.53% |
| 2013 Q3 | -5.35 Million USD | 13.41% |
| 2013 FY | - USD | -31.5% |
| 2013 Q4 | -6.51 Million USD | -21.73% |
| 2013 Q1 | -7.05 Million USD | 0.0% |
| 2013 Q2 | -6.18 Million USD | 12.35% |
| 2012 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Abbott Laboratories | 10.46 Billion USD | 100.748% |
| Allurion Technologies Inc. | -69.03 Million USD | -13.442% |
| Artivion, Inc. | 38.14 Million USD | 305.312% |
| Avanos Medical, Inc. | 53.2 Million USD | 247.199% |
| Butterfly Network, Inc. | -124.84 Million USD | 37.274% |
| Butterfly Network, Inc. | -124.84 Million USD | 37.274% |
| Bio-Rad Laboratories, Inc. | -608.26 Million USD | 87.126% |
| Boston Scientific Corporation | 3.45 Billion USD | 102.268% |
| Perspective Therapeutics, Inc. | -14.83 Million USD | -427.767% |
| CONMED Corporation | 182.18 Million USD | 142.984% |
| Edwards Lifesciences Corporation | 1.76 Billion USD | 104.43% |
| Paragon 28, Inc. | -36.61 Million USD | -113.88% |
| Glaukos Corporation | -82.11 Million USD | 4.635% |
| Globus Medical, Inc. | 418.23 Million USD | 118.724% |
| Inspire Medical Systems, Inc. | -17.06 Million USD | -359.027% |
| Integer Holdings Corporation | 282.05 Million USD | 127.764% |
| Medtronic plc | 9.05 Billion USD | 100.865% |
| Owlet, Inc. | -27.48 Million USD | -184.878% |
| Penumbra, Inc. | 111.99 Million USD | 169.922% |
| Vicarious Surgical Inc. | -69.19 Million USD | -13.178% |
| Smith & Nephew plc | 979 Million USD | 107.999% |
| Sonendo, Inc. | -54.76 Million USD | -42.985% |
| STERIS plc | 1.41 Billion USD | 105.544% |
| Stryker Corporation | 5.16 Billion USD | 101.518% |
| Vapotherm, Inc. | -34.35 Million USD | -127.93% |
| Zimmer Biomet Holdings, Inc. | 2.44 Billion USD | 103.198% |